Mark E Schmidt

List of Publications by Year
in descending order

88 papers	4,535 citations	145106 33 h-index	120465 65 g-index
89 all docs	89 docs citations	89 times ranked	7159 citing authors

#	Article	IF	Citations
1	Modulating the Endocannabinoid System as a Therapeutic Approach for Posttraumatic Stress Disorder: Could Translational Research on Fear and Extinction Learning Predict Clinical Benefit?. Biological Psychiatry, 2022, 91, 248-249.	0.7	0
2	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 2022, 27, 1286-1299.	4.1	68
3	Brain Imaging for Alzheimerâ€™s Disease Clinical Trials. , 2022, , 375-394.		0
4	Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	1.8	2
5	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.4	44
6	Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers. NeuroImage, 2021, 230, 117785.	2.1	6
7	Uncertainty analysis of MR-PET image registration for precision neuro-PET imaging. NeuroImage, 2021, 232, 117821.	2.1	8
8	Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function. Scientific Reports, 2021, 11, 16172.	1.6	6
9	Translational Modelâ€Informed Dose Selection for a HumanÂPositron Emission Tomography Imaging Study of JNJâ€54175446, a P2X7 Receptor Antagonist. Clinical and Translational Science, 2020, 13, 309-317.	1.5	2
10	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.5	55
11	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.4	29
12	[11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinsonâ€™s disease and healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2051-2064.	3.3	55
13	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.4	37
14	¹⁸F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. Journal of Nuclear Medicine, 2019, 60, 683-690.	2.8	63
15	Fatty Acid Amide Hydrolase Inhibition by JNJâ€42165279: A Multipleâ€Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers. Clinical and Translational Science, 2018, 11, 397-404.	1.5	36
16	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology, 2018, 90, e877-e886.	1.5	28
17	Secondary prevention of Alzheimerâ€™s dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	3.0	46
18	Discovery of N-(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2017, 60, 1272-1291.	2.9	31

#	Article	IF	Citations
19	Preclinical Evaluation of¹⁸F-JNJ64349311, a Novel PET Tracer for Tau Imaging. Journal of Nuclear Medicine, 2017, 58, 975-981.	2.8	72
20	Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease. Journal of Nuclear Medicine, 2017, 58, 1977-1983.	2.8	24
21	The value of PET ligand discovery to CNS drug development. Future Medicinal Chemistry, 2017, 9, 351-356.	1.1	3
22	What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2. Journal of Nuclear Medicine, 2017, 58, 110-116.	2.8	31
23	Medicinal Chemistry strategies for PET tracer discovery. Drug Discovery Today: Technologies, 2017, 25, 11-17.	4.0	5
24	The Effects of Physiological and Methodological Determinants on ¹⁸F-FDG Mouse Brain Imaging Exemplified in a Double Transgenic Alzheimer Model. Molecular Imaging, 2016, 15, 153601211562491.	0.7	21
25	Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model. Journal of Alzheimer's Disease, 2016, 55, 1537-1548.	1.2	15
26	Preclinical Evaluation of a P2X7 Receptorâ€“Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates. Journal of Nuclear Medicine, 2016, 57, 1436-1441.	2.8	77
27	In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-Î² load in aged APPPS1-21 mice. Alzheimer's Research and Therapy, 2015, 7, 76.	3.0	27
28	Preclinical Comparison of the Amyloid-Î² Radioligands [11C]Pittsburgh compound B and [18F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis. Molecular Imaging and Biology, 2015, 17, 688-696.	1.3	8
29	Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). Alzheimer's and Dementia, 2015, 11, 840-849.	0.4	10
30	Amyloid-Î² ¹¹ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology, 2015, 85, 692-700.	1.5	136
31	The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimer's and Dementia, 2015, 11, 1050-1068.	0.4	98
32	Quantitative Î¼PET Imaging of Cerebral Glucose Metabolism and Amyloidosis in the TASTPM Double Transgenic Mouse Model of Alzheimerâ€™s Disease. Current Alzheimer Research, 2015, 12, 694-703.	0.7	14
33	Imaging as a biomarker in drug discovery for Alzheimerâ€™s disease: is MRI a suitable technology?. Alzheimer's Research and Therapy, 2014, 6, 51.	3.0	24
34	The [¹⁸F]FDG Î¼PET Readout of a Brain Activation Model to Evaluate the Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator JNJ-42153605. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 375-386.	1.3	12
35	PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology, 2014, 82, 279-281.	1.5	78
36	Dimensions in major depressive disorder and their relevance for treatment outcome. Journal of Affective Disorders, 2014, 155, 35-41.	2.0	99

#	Article	IF	Citations
37	Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A. Nuclear Medicine and Biology, 2014, 41, 695-704.	0.3	15
38	IC-P-044: LONGITUDINAL MONITORING OF Î²-AMYLOID PATHOLOGY AND CEREBRAL HYPOMETABOLISM IN A DOUBLE TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE. , 2014, 10, P27-P27.		1
39	Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping. EJNMMI Research, 2013, 3, 10.	1.1	1
40	Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 254-261.	3.3	36
41	Population Pharmacokinetics of JNJ-37822681, a Selective Fast-Dissociating Dopamine D2-Receptor Antagonist, in Healthy Subjects and Subjects with Schizophrenia and Dose Selection Based on Simulated D2-Receptor Occupancy. Clinical Pharmacokinetics, 2013, 52, 1005-1015.	1.6	3
42	Reduced Reward Learning Predicts Outcome in Major Depressive Disorder. Biological Psychiatry, 2013, 73, 639-645.	0.7	325
43	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2013, 9, e111-94.	0.4	535
44	Does early improvement predict response to the fast-dissociating D2 receptor antagonist JNJ-37822681 in patients with acute schizophrenia? â˜† . European Neuropsychopharmacology, 2013, 23, 1043-1050.	0.3	3
45	Positron Emission Tomography in Alzheimer Disease. , 2013, , 131-174.		3
46	Quantification of ¹⁸F-JNJ-42259152, a Novel Phosphodiesterase 10A PET Tracer: Kinetic Modeling and Testâ€“Retest Study in Human Brain. Journal of Nuclear Medicine, 2013, 54, 1285-1293.	2.8	43
47	N-Acetylcysteineâ€“ and MK-801â€“Induced Changes in Glutamate Levels Do Not Affect In Vivo Binding of Metabotropic Glutamate 5 Receptor Radioligand ¹¹C-ABP688 in Rat Brain. Journal of Nuclear Medicine, 2013, 54, 1954-1961.	2.8	34
48	In vivo quantification of striatal dopamine D₂receptor occupancy by JNJ-37822681 using [¹¹C]raclopride and positron emission tomography. Journal of Psychopharmacology, 2012, 26, 1128-1135.	2.0	17
49	Applications of Imaging Biomarkers in the Early Clinical Development of Central Nervous System Therapeutic Agents. Clinical Pharmacology and Therapeutics, 2012, 91, 315-320.	2.3	11
50	A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia. European Neuropsychopharmacology, 2012, 22, 721-733.	0.3	24
51	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2012, 8, S1-68.	0.4	432
52	D2-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D2-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection. Psychopharmacology, 2012, 224, 549-557.	1.5	5
53	A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses. International Journal of Neuropsychopharmacology, 2011, 14, 355-365.	1.0	19
54	Dose-dependent effects of the CRF1 receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology, 2010, 208, 109-119.	1.5	30

#	Article	IF	Citations
55	Preclinical Evaluation of ¹⁸F-JNJ41510417 as a Radioligand for PET Imaging of Phosphodiesterase-10A in the Brain. Journal of Nuclear Medicine, 2010, 51, 1584-1591.	2.8	64
56	The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. Alzheimer's and Dementia, 2010, 6, 202.	0.4	443
57	The Alzheimer's Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory Board. Alzheimer's and Dementia, 2010, 6, 286-290.	0.4	9
58	Television Viewing in Infancy and Child Cognition at 3 Years of Age in a US Cohort. Pediatrics, 2009, 123, e370-e375.	1.0	129
59	Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 766-770.	3.3	30
60	Evaluation of the Metabotropic Glutamate Receptor Subtype 5 Using PET and 11C-ABP688: Assessment of Methods. Journal of Nuclear Medicine, 2007, 48, 1207-1215.	2.8	68
61	Quantitative evaluation of 11C-ABP688 as PET ligand for the measurement of the metabotropic glutamate receptor subtype 5 using autoradiographic studies and a beta-scintillator. NeuroImage, 2007, 35, 1086-1092.	2.1	37
62	A Comparison of Brain and Serum Pharmacokinetics of R-Fluoxetine and Racemic Fluoxetine: A 19-F MRS Study. Neuropsychopharmacology, 2005, 30, 1576-1583.	2.8	75
63	Central nervous system drug development: An integrative biomarker approach toward individualized medicine. NeuroRx, 2005, 2, 683-695.	6.0	28
64	Chronic Lithium Administration Enhances Noradrenergic Responses to Intravenous Administration of the Î±2 Antagonist Idazoxan in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2004, 24, 150-154.	0.7	4
65	Long-Term Treatment Outcomes of Depression With Associated Anxiety. Journal of Clinical Psychiatry, 2004, 65, 373-378.	1.1	11
66	Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment. Biological Psychiatry, 2003, 53, 100-105.	0.7	11
67	Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. Biological Psychiatry, 2003, 54, 534-539.	0.7	21
68	Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo. Nuclear Medicine and Biology, 2003, 30, 187-190.	0.3	6
69	Treatment Approaches to Major Depressive Disorder Relapse. Psychotherapy and Psychosomatics, 2002, 71, 190-194.	4.0	55
70	Treatment Approaches to Major Depressive Disorder Relapse. Psychotherapy and Psychosomatics, 2002, 71, 195-199.	4.0	40
71	The Effects of ECT on Brain Glucose: A Pilot FDG PET Study. Journal of ECT, 2001, 17, 33-40.	0.3	61
72	The Future of Imaging in Drug Discovery. Journal of Pharmacy Practice, 2001, 14, 427-434.	0.5	0

#	Article	IF	Citations
73	Brain Kinetics of Paroxetine and Fluoxetine on the Third Day of Placebo Substitution: A Fluorine MRS Study. American Journal of Psychiatry, 2000, 157, 1506-1508.	4.0	55
74	Novel Radiotracers for Imaging the Serotonin Transporter by Positron Emission Tomography:Â Synthesis, Radiosynthesis, and in Vitro and ex Vivo Evaluation of11C-Labeled 2-(Phenylthio)araalkylamines. Journal of Medicinal Chemistry, 2000, 43, 3103-3110.	2.9	242
75	The Efficacy and Safety of a New Enteric-Coated Formulation of Fluoxetine Given Once Weekly During the Continuation Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry, 2000, 61, 851-857.	1.1	58
76	Patient Compliance to a New Enteric-Coated Weekly Formulation of Fluoxetine During Continuation Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry, 2000, 61, 928-932.	1.1	36
77	Cerebral glucose metabolic and plasma catecholamine responses to the ? 2 adrenoceptor antagonist ethoxyidazoxan given to healthy volunteers. Psychopharmacology, 1999, 146, 119-127.	1.5	6
78	The Future of Imaging in Drug Discovery. Journal of Clinical Pharmacology, 1999, 39, 45S-50S.	1.0	4
79	Responses to Î±2-adrenoceptor blockade by idazoxan in healthy male and female volunteers. Psychoneuroendocrinology, 1997, 22, 177-188.	1.3	17
80	Gender Differences in Brain Metabolic and Plasma Catecholamine Responses to Alpha2-Adrenoceptor Blockade. Neuropsychopharmacology, 1997, 16, 298-310.	2.8	31
81	Intravenous Dextroamphetamine and Brain Glucose Metabolism. Neuropsychopharmacology, 1997, 17, 391-401.	2.8	33
82	Acute alpha 2 blockade by idazoxan increases insulin and lowers plasma glucose during positron emission tomography. Psychopharmacology Bulletin, 1997, 33, 253-9.	0.0	5
83	Cerebral glucose metabolism during pharmacologic studies: test-retest under placebo conditions. Journal of Nuclear Medicine, 1996, 37, 1142-9.	2.8	23
84	Regional brain glucose metabolism after acute Î±2-blockade by idazoxan. Clinical Pharmacology and Therapeutics, 1995, 57, 684-695.	2.3	12
85	Carbamazepine increased pregnenolone synthesis blocked by peripheral type benzodiazepine receptor antagonist. Depression, 1995, 3, 267-272.	0.7	1
86	The effects of prolonged lithium exposure on the immune system of normal control subjects: Serial serum soluble interleukin-2 receptor and antithyroid antibody measurements. Biological Psychiatry, 1994, 35, 761-766.	0.7	21
87	Effect of dextroamphetamine and methylphenidate on calcium and magnesium concentration in hyperactive boys. Psychiatry Research, 1994, 54, 199-210.	1.7	13
88	Urinary Free Cortisol Output and Disruptive Behavior in Children. Journal of the American Academy of Child and Adolescent Psychiatry, 1989, 28, 441-443.	0.3	79